Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $119.63M.
ENTERPRISE VALUE (EV)
$119.63M
Entrada Therapeutics, Inc.
Market Cap
$210.02M
Enterprise Value (EV)
$119.63M
Market Cap
$210.24M
Enterprise Value (EV)
$202.47M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | $210.02M | $119.63M |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $210.24M | $202.47M |
| Compugen Ltd. (CGEN)vs › | $210.85M | $203.60M |
| Pro-Dex, Inc. (PDEX)vs › | $208.63M | $218.53M |
| Sionna Therapeutics, Inc. (SION)vs › | $208.59M | $153.34M |
| Niagen Bioscience Inc (NAGE)vs › | $212.25M | $147.84M |
| Lyell Immunopharma, Inc. (LYEL)vs › | $212.75M | $176.70M |
| Prelude Therapeutics Incorporated (PRLD)vs › | $213.78M | $205.10M |
| Electra Therapeutics Inc. (ETRA)vs › | $205.02M | N/A |
| Whitehawk Therapeutics Inc (WHWK)vs › | $204.38M | $119.14M |
Market Cap
$210.02M
Total Debt
$0.00
Cash
$90.39M
Enterprise Value
$119.63M
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
